Evidence map›Paper›PMID 34795309›Full record

ArticleScientific reports2021

Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer.

Yanlong Zhang, Xuezhi Liang, Liyun Zhang, Dongwen Wang

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Mechanisms Underlying the Rarity of Skeletal Muscle Cancers.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yanlong Zhang *Department of Urology, First Hospital of Shanxi Medical University, 85 Jiefang Street, 030001, Taiyuan City, Shanxi Province, China.
Xuezhi Liang *Department of Urology, First Hospital of Shanxi Medical University, 85 Jiefang Street, 030001, Taiyuan City, Shanxi Province, China.
Liyun ZhangDepartment of Rheumatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, 99 Longcheng Street, 030032, Taiyuan City, Shanxi Province, China. 1315710223@qq.com.
Dongwen WangDepartment of Urology, First Hospital of Shanxi Medical University, 85 Jiefang Street, 030001, Taiyuan City, Shanxi Province, China. urology2007@126.com.

Funding

National Natural Science Foundation of China 81771768
6 · The paper itself

Abstract

Tumor metabolism patterns have been reported to be associated with the prognosis of many cancers. However, the metabolic mechanisms underlying prostate cancer (PCa) remain unknown. This study aimed to explore the metabolic characteristics of PCa. First, we downloaded mRNA expression data and clinical information of PCa samples from multiple databases and quantified the metabolic pathway activity level using single-sample gene set enrichment analysis (ssGSEA). Through unsupervised clustering and principal component analyses, we explored metabolic characteristics and constructed a metabolic score for PCa. Then, we independently validated the prognostic value of our metabolic score and the nomogram based on the metabolic score in multiple databases. Next, we found the metabolic score to be closely related to the tumor microenvironment and DNA mutation using multi-omics data and ssGSEA. Finally, we found different features of drug sensitivity in PCa patients in the high/low metabolic score groups. In total, 1232 samples were analyzed in the present study. Overall, an improved understanding of tumor metabolism through the characterization of metabolic clusters and metabolic score may help clinicians predict prognosis and aid the development of more personalized anti-tumor therapeutic strategies for PCa.

Indexed as

Antineoplastic AgentsBiomarkers, TumorCluster AnalysisComputational BiologyComputer SimulationDatabases, GeneticDNA Mutational AnalysisGene Expression ProfilingGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansKaplan-Meier EstimateMalePredictive Value of TestsPrincipal Component AnalysisPrognosisAntineoplastic AgentsBiomarkers, TumorRNA, Messenger

Identifiers

PMID34795309
PMCPMC8602249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.